logo-loader

Cynata Therapeutics Ltd to update on clinical trial

Published: 11:00 19 Sep 2016 AEST

au_medical_chart350_57df4156a5435

Cynata Therapeutics Ltd (ASX:CYP) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Cynata requested the halt pending details regarding the company’s clinical trial authorisation application for its lead Cymerus mesenchymal stem product with the UK Medicines and Health Care Product Regulatory Agency (MHRA).

The halt will remain in place until the opening of trade on Wednesday 21st September 2016, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

13 hours, 42 minutes ago